Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
23472470
Knihovny.cz E-zdroje
- MeSH
- antiflogistika analýza MeSH
- benzochinony farmakologie MeSH
- chinony farmakologie MeSH
- inhibitory cyklooxygenasy 2 analýza MeSH
- inhibitory lipoxygenas analýza MeSH
- léčivé rostliny chemie MeSH
- leukotrien B4 antagonisté a inhibitory biosyntéza MeSH
- lidé MeSH
- neutrofily účinky léků metabolismus MeSH
- preklinické hodnocení léčiv MeSH
- rostlinné extrakty chemie farmakologie MeSH
- simulace molekulového dockingu MeSH
- thymol analogy a deriváty farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antiflogistika MeSH
- benzochinony MeSH
- chinony MeSH
- inhibitory cyklooxygenasy 2 MeSH
- inhibitory lipoxygenas MeSH
- leukotrien B4 MeSH
- primin MeSH Prohlížeč
- rostlinné extrakty MeSH
- thymohydroquinone MeSH Prohlížeč
- thymol MeSH
Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B4 (LTB4) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC50 = 4.0 and 4.1 microM, respectively) showed activity comparable with the reference inhibitor zileuton (1C50 = 4.1 microM). Moderate activity was observed for the benzoquinone thymoquinone (2) (1C50 = 18.2 microM) and the naphthoquinone shikonin (1) (IC50 = 24.3 microM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC50 > 50 microM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.